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Background: Problems related to poor adherence and inhaler technique (IT) are historically 
reported in the literature. Most common methods used for adherence and IT assessment are 
reported to be either inaccurate or subjective. Few electronic monitoring devices (EMDs) that 
provide an objective measure of both adherence and IT while patients use inhalers at home 
now exist. Therefore, this study aimed to examine adherence level and IT among respiratory 
patients in community care using such an EMD for the first time in England. 
 
Methods: A prospective, multicentre, observational cohort study was conducted. Patients 
with Chronic Obstructive Pulmonary Disease (COPD) or asthma were recruited from 
independent community pharmacies within West and South London. Patients were provided 
with a dry powder inhaler (DPI) mounted with an EMD to use for 1 month. Adherence was 
also assessed using pharmacy dispensing data, inhaler dose-counter and self-reporting. 
 
Results:  Data were available for 48 patients. Only 8 patients used their inhaler in the correct 
manner at the correct interval as identified by the chosen EMD. The median actual adherence 
rate, as measured by the EMD, was 42.7%. This was significantly different from the median 
dose-counter adherence (100%), medication refill adherence (100%), proportions of days 
covered (97.8%) and self-reported adherence (p<0.001, each). Within a one-month period, 
there were 2188 files showing attempted use of the DPI, of which 840 had IT errors. The 
median technique error rate was 30.1%. Most common errors recorded were: multiple 
inhalations, drug priming without inhalation and failure to prime the device correctly.  
 
Conclusion: The current study demonstrates that measures such as dose-counter, 
prescription-refill and self-reporting showed a high level of adherence among the observed 
patients. However, the objective data provided by the EMD showed a significantly lower 
actual adherence rate, reflecting how adherence remains variable and problematic among 
patients in the community.  
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What is already known about the topic? 
• Problems of poor adherence and IT are historically reported in the literature among 
respiratory patients, with no signs of substantial improvement. 
• Accurate assessment of adherence and IT is difficult in clinical practice, with 
traditional methods being reported either as inaccurate or subjective. 
What does this article add?  
• Using an EMD that assesses both adherence and IT, this study identified that the actual 
adherence among patients over a one-month period was as low as 42.7%.  
• Only 17% of patients used their inhaler correctly and on time, echoing observations from 
patients in Ireland.  
• Actual adherence was significantly lower compared to the currently established methods of 
adherence assessment such as dose-counter, self-reporting and prescription-refill, which calls 



























Over half of a billion people suffer from chronic respiratory conditions such as asthma or 
chronic obstructive pulmonary disease (COPD) 1,2. The two conditions are considered as major 
public health challenges with substantial clinical, social and economic burdens worldwide 3-9. 
Inhalation therapy is of paramount importance in the treatment of respiratory conditions 3,6,10-
13. However, problems related to poor adherence and inhaler technique (IT) among respiratory 
patients are widely and historically reported in the literature and still represent a challenge for 
healthcare professionals (HCPs) and healthcare systems to date 3,4,14-19. Regarding IT, evidence 
in the literature suggests that 50-100% of patients perform errors while using their inhalers 
18,20,21 . Furthermore, the literature suggests that deterioration in technique can occur as early 
as one month after receiving education about IT 22,23. In terms of adherence, the evidence in 
the literature indicates that adherence rates among respiratory patients can widely vary ranging 
from 22%-78% and sometimes can be as low as 10-40% 8,24,25. Poor adherence and IT are two 
aspects that significantly contribute to poor disease control leading to prescribing unnecessary 
higher doses, increased frequency of exacerbations and hospitalisation, high mortality, low 
quality of life and loss of productivity, hence increasing the clinical and economic burdens of 
these conditions 3-9. For respiratory patients, some scholars argue for the incorrect use of 
inhalers to be a form of poor adherence or non-adherence 18,24,26. Other scholars see that poor 
adherence can be triggered by the incorrect IT of the patient because of the latter’s 
dissatisfaction with the medication response 9,10. Whereas a third group of scholars 27-31 
highlight that the notion of what is called true adherence incorporates two distinct components 
namely adherence and competence, with competence mainly being related to the patient’s 
ability to use a medication in a correct and effective way which is also commonly referred to 
as technique. Hence, in case of inhaled medication, adherence and IT should be taken into 
consideration to reflect true adherence. 
Unfortunately, there is no evidence in the literature for any substantial change/ improvement 
in the problem of incorrect IT over the past four decades 9,21,32-34, or the problem of adherence 
to medications used in the treatment of long-term conditions (LTCs) over the past five 
decades 35. This is further escalated by the fact that the most common methods currently used 
for adherence and IT assessment are reported to be either inaccurate or subjective 15,29,36-38. 
The use of electronic monitoring devices (EMDs), on the other hand, have been reported to 
provide a more accurate solution for monitoring IT and adherence to therapy for asthma and 
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COPD patients 39. However, some of these EMDs assess adherence alone, whereas, others 
assess IT alone 38.  The inhaler compliance assessment device, commercially referred to 
under the trademark of INCA, is one of the few EMDs that has the advantage of being an 
automatic and objective measure of both adherence and IT while patients are using their 
inhalers at home 29, 37,40, 41. The aforementioned device is a small acoustic, battery-operated 
device that is mounted on the top of a dry powder inhaler (DPI) (Figure 1). Once the inhaler 
is opened, the device becomes activated and starts recording the audio associated with inhaler 
use, in addition to the date and time and switches off once the DPI is closed 29,42 . Analysis of 
the recorded audio-files is conducted by an automated processing algorithm to provide 
quantitative information about the patients’ technique, time and duration of inhaler use 30. 
The device algorithm has an accuracy of 89%, sensitivity of 95% and specificity of 94% in 
detecting and determining inhaler technique steps related to inhalation, exhalation and drug 
priming 36. The design and validation of the device has been previously published 29,36,38,42-45 . 
The device is certified (EU registered) 30 and has Food and Drug Administration (FDA) 
approval 22, 46 .  
So far, studies involving the aforementioned device were only conducted in Ireland30,47. The 
Irish studies looked at assessing adherence and IT of asthma and COPD patients using the 
EMD. Interestingly, the Irish studies found that ineffective and irregular use is common among 
respiratory patients with only 20% of patients in the community30 and 6% of patients after 
hospital discharge47 using their inhaler correctly and on time.  Therefore, the primary aim of 
this study was to examine the level of adherence and IT of COPD and asthma patients using 
this device for the first time in England. The secondary aims were to compare the 
abovementioned EMD as an adherence measure with established measures of adherence such 
as prescription-refill, the inhaler dose-counter and self-reporting. In addition, to identify and 




2.1. Study design 
The current study quantified over a one-month period how and when two cohorts of respiratory 
patients, asthma and COPD, recruited from several community pharmacies used a twice-daily 
preventer inhaler. Thus, this study was considered a prospective, multi-centre, observational 
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cohort study in a community care setting. Twenty-three independent community pharmacies 
based in South and West London participated in this study. A convenience sampling strategy 
based on local knowledge and proximity to the research team in England was employed for 
recruiting community pharmacies. A list of independent community pharmacies was identified 
through the National Health Service (NHS) choices website for pharmacies located within 
West and South London. Multiple chain pharmacies were excluded due to research governance 
requirements. Ethical approval for conducting this study was granted from the Research Ethics 
Committee at the academic institution of the corresponding author (Reference No. 1415/034). 
The study was initiated in October 2015 and was completed in June 2017. 
2.2. Procedures 
Patients were recruited from the participating community pharmacies. Inclusion criteria for 
patients were as follows: over 18 years old, diagnosed with asthma or COPD, using a 
combination long acting beta-agonist/inhaled corticosteroid inhaler: salmeterol/fluticasone 
DPI for at least 6 months, regular customers of the participating pharmacies, capable of 
understanding and willing to provide voluntary informed consent. Patients were excluded if 
they were under 18 years of age, illiterate or with language barrier, not using 
salmeterol/fluticasone DPI, mentally incapacitated, or involved in another study at time of 
recruitment. Patients were recruited by community pharmacists, hence inclusion and exclusion 
criteria were provided by the research team to the participating pharmacists in order to guide 
the recruitment process. Written informed consent was obtained from each patient by the 
corresponding community pharmacist prior to study start. 
Once informed consent was obtained from patients, the chosen EMD was mounted on the top 
of their DPI. Patients were asked to use the mounted DPI as usual and return it to the 
pharmacy when they finish it (i.e.: after one month). No training about IT was provided to the 
patients because the main aim of the study was to assess the patients’ level of adherence and 
IT in a real-world setting. Demographic data on age, gender, educational level, marital status, 
socioeconomic class, clinical diagnosis, healthcare utilisation and self-reported adherence 
were obtained from participants. Furthermore, patients’ medication refill data for the 
salmeterol/fluticasone DPI was retrospectively obtained for the last 6 months prior study start 




2.3. Outcome measures   
Adherence to maintenance therapy (salmeterol/fluticasone DPI)  
Objective adherence: the adherence rate for each patient measured using the chosen EMD 
was calculated as an area under the curve (AUC) metric. This method of adherence calculation 
was previously described in details by Sulaiman et al 31. Initially, the AUC was calculated for 
the patient’s “attempted adherence”. Afterwards, the AUC was calculated for the patient’s 
“actual adherence”, which denotes attempted adherence at the correct intervals with no 
technique errors 47,48.  
Dose counter adherence: this was calculated by dividing the number of doses used according 
to the dose counter by the total expected doses to be taken monthly, which is 60, multiplied by 
100.  
Prescription refill adherence: This was assessed retrospectively using medication refill 
adherence (MRA) 49 and proportions of days covered (PDC) 50 for a six-month period prior 
study start for the salmeterol/fluticasone DPI.   
Self-reported adherence: the modified version of inhaler adherence scale (IAS) was used51-
53. The scale consists of four questions with five-point Likert scale responses, with 1 indicating 
“Most of the time” and 5 indicating “None of the time” for the frequency of forgetting or 
stopping the use of the maintenance inhaler. Higher scores reflect better adherence to inhalation 
therapy53,54. The IAS score was calculated from the mean responses to the four questions. Thus, 
the mean IAS score can range from 1 to 5, with 5 indicating optimal adherence. The modified 
scale has good psychometric properties (Cronbach α =0.86) 53.  
Based on the literature 4,49,55-57, the cut-off point for a patient to be considered as adherent is 
having a value of ≥ 80% for the dose counter, MRA, PDC and the EMD adherence measures. 
As for self-reported adherence, an overall IAS score of ≥4 was considered as having good 
adherence, whereas a mean score of <4 was considered as having some level of poor adherence 
54.  
 
Inhaler technique  
IT was assessed objectively and quantitatively for one month using the chosen EMD. The 
technique error rate (TER) for a one-month period was calculated by dividing the number of 
files with technique errors by the total number of files when the inhaler was used, multiplied 
by 100. According to literature, a cut-off point of ≥80% is widely used to indicate good 
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adherence 4,49,55-57, and since IT is a form of non-adherence 18,24,26; therefore, a TER of >20% 
was considered as a form of poor IT in the current study. 
2.4. Statistical analysis  
Descriptive statistics were performed to describe characteristics of patients and errors in inhaler 
use. Mean and standard deviation (SD) were used to describe continuous variables with normal 
distribution. Continuous variables that were not normally distributed were expressed using 
median and range. Proportions/percentages were used to describe categorical variables. In 
addition, frequencies were used to describe the distribution of different inhaler errors. The 
normality of data distribution was tested using Shapiro Wilk test 58. Continuous/scale variables 
with normal distribution were compared using t-tests; whereas for variables that were not 
normally distributed, this was performed using Wilcoxon signed-rank test.  
Correlations between data were analysed using Kendall tau-b rank correlation coefficient 
(denoted by τb) for non-normally distributed data. Furthermore, adherence variables were 
classified as binary based on the adherence level into good adherence and poor adherence. 
Good adherence level was based on a cut-off point of ≥ 80% for adherence measures via the 
EMD, dose counter, PDC and MRA and a cut-off point of ≥ 4 for the IAS self-reported 
adherence, and poor level otherwise 4,49,54-57. These binary variables were then correlated using 
Phi correlation coefficient (denoted by rφ).  
Analysis was performed using SPSS for Windows version 23. The level of statistical 
significance was set at p<0.05 for all analyses. 
 
3. Results: 
3.1. Study population and demographics:  
Fifty-five patients were recruited over the study period and provided with a DPI mounted with 
the EMD. Four patients (7.2%) did not return the mounted DPI, one patient (1.8%) withdrew 
from the study, and two EMDs (3.6%) were not functional.  Therefore, 48 patients with usable 
information were included in the study. The median age of participants was 65 years, with 60% 
(n=29) diagnosed with COPD and 40% (n=19) diagnosed with asthma. Demographic 




3.2. Adherence level among COPD and asthma patients using the 
designated EMD 
Acoustic recordings were available for 48 patients; 2880 doses were expected to be taken in a 
one-month period (48*60 =2880 doses). The total number of doses taken according to the dose 
counter for the 48 patients was 2843, however there were 2601 audio files of attempted use by 
the EMD. This difference was attributed to errors related to drug priming.  
Although patients were instructed to return their DPI after one month, many patients used their 
DPI beyond the ideal 30 days period. Therefore, audio files beyond one-month period were 
excluded from the analysis. Adjusting for one-month usage, there were 2188 audio files 
recorded with attempted use and 1348 audio files with correct technique (i.e.: actual doses). Of 
60 doses expected to be taken monthly per patient, a median of 51 (85%) doses were attempted 
and when technique errors were accounted for, the median number of actual doses was 30 
(50%). 
Most patients used their DPI irregularly, in contrast to the twice per day, twelve hours apart 
regime, as there were periods of excessive dosing (≥ 3 doses in 24 hours) and periods of missed 
doses (<2 doses in 24 hours), accounting for 118 extra doses and 510 missed doses within one-
month period. In fact, more than two-third of patients (69%, n=33) had periods of excessive 
dosing and 92% (n=44) had periods of missed dosing. Only 8% of patients (n=4) did not have 
any periods of missed dosing and excessive dosing during the one-month period. 
 
The median attempted adherence using the EMD was 72.7% (range: 15.9-100) (Table 2). 
Notably, 40% of patients had attempted adherence rate between 80-100%, followed by one-
third of patients (33%) having attempted adherence rate between 60-79%, 10.5% with 
adherence rates between 40-59%, 12.5% had attempted adherence rate between 20-39%, and 
only 2 patients (4%) had very low attempted adherence rate between 0-19% (Table 3).With a 
cut-off point of 80% for good adherence, 40% of patients had an attempted adherence ≥ 80% 
and 60% had a rate <80% (Table 4).When the interval between doses and technique errors were 
included in the adherence calculation, the median actual adherence using the EMD was 42.7% 
(range: 0-96.4) (Table 2). Interestingly, nearly one third of patients (31%) had very low actual 
adherence rate (0%-19%), 14.5% had adherence rate between 20-39% and 40-59% equally, 
23% had actual adherence rate between 60-79% with only 17% having actual adherence rate 
between 80-100% (Table 5).  Based on a cut-off point of 80% for good adherence , only 8 
patients (17%) out of 48 used their inhaler in the correct manner at the correct interval, i.e.: had 
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an actual adherence ≥80%, whereas the majority (83%) had an actual adherence rate <80% 
(Table 4). Significant difference was observed between attempted adherence and actual 
adherence (p<0.001). Although COPD patients had higher attempted adherence compared to 
asthma patients, yet statistical analysis did not reveal any significant difference (p=0.089). 
Furthermore, there was no significant difference in the actual adherence rate between asthma 
and COPD patients (p=0.649). 
 
3.3. Comparison of adherence from the designated EMD with the other 
established adherence measures  
The median number of doses taken from dose counter was 60 doses and the median adherence 
rate using this method was 100% (range: 76.7-100) (Table 2). Dose-counter adherence rate was 
significantly different from the attempted adherence rate (p<0.001) and the actual adherence 
rate (p<0.001) obtained via the EMD. According to this method for assessing adherence, only 
one patient (2%) had an adherence rate <80% (Table  4), whereas 40 patients (83%) had an 
actual adherence rate <80% as measured by the EMD. No significant associations were found 
between dose-counter adherence with attempted adherence (rφ =.118, p=0.413) or actual 
adherence (rφ =.065, p=0.651) as measured by the EMD.  
The median MRA was 100% (range: 33.3-133.3). MRA was significantly different from both 
attempted and actual adherence rates (p<0.001, each) as measured by the EMD. When using 
MRA for assessing adherence, 19% of patients had a MRA<80% and 81% had an adherence 
rate ≥ 80% (Table  4). Thus, there were 39 patients with MRA≥ 80% as opposed to only 8 
patients having an actual adherence ≥80% as indicated by the EMD. No significant associations 
were found between MRA with attempted adherence (rφ =.061, p=0.671) or actual adherence 
(rφ =.215, p=0.137) as measured by the EMD. 
 The median PDC was 97.8% (range: 33.3-100). PDC adherence rate was significantly different 
from attempted adherence rate (p<0.001) and actual adherence rate (p<0.001) as measured by 
the EMD. When using PDC for assessing adherence, 77% of patients (n=37) were found to 
have an adherence rate ≥ 80%, and 23% had a PDC<80% (Table  4), compared to 17% (n=8) 
having an actual adherence ≥80% as measured by the EMD No significant associations were 
found between PDC with attempted adherence (rφ =.137, p=0.342) or actual adherence (rφ 
=.244, p=0.091) as indicated by the EMD.  
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As for self-reported adherence, the overall mean IAS score was 4.43 (95% CI: 4.2-4.6) (Table 
2). Nearly half of the patients (n=23/48, 48%) had an overall mean score of 5 indicating optimal 
adherence. Based on a cut-off point of 4 for good adherence 53, 39 patients (81%) were 
classified as having good adherence and 9 (19%) showed some level of poor adherence. There 
was a significant difference between patients’ self-reported adherence and each of attempted 
and actual adherence rates (p<0.001) obtained via the EMD. Interestingly, a significant positive 
association was observed between self-reported adherence and attempted adherence (rφ 
=0.389, p=0.007) as measured by the EMD, but not with actual adherence (rφ =.215, p=0.137). 
A possible explanation for that would be the fact that calculating actual adherence via the EMD 
takes into account errors in IT and interval between doses, which are not perceived by patients 
as a form of non-adherence. However, attempted adherence as generated by the EMD does not 
take into account technique errors or dose interval.  
3.4. Inhaler technique among COPD and asthma patients using the 
designated EMD 
The median TER per patient was 30.1% (range: 0-100) (Table 6) indicating an overall poor 
level of IT among the observed patients, based on a cut-off point of 20%. Analysis of the audio 
data showed that 1348 files (62%, n=1348/2188) followed the correct technique of inhaler use 
and 840 (38%, n=840/2188) had errors in the technique in a one-month period. Errors in drug 
priming which is the first step in inhaler use accounted for 17.4% (n=146/840) of all errors 
(Table 7). There were 26 audio files (3.2%) with evidence of more than one drug blister 
with/without inhalation which suggests dose wasting. Errors in inhalation accounted for 82.6% 
(n=694/840) of all errors. Multiple inhalations was the most prevalent error as it was recorded 
in 49.5% (n= 416/840) of all events, followed by drug priming without subsequent inhalation 
which accounted for 29.5% of all errors and lastly failure to prime the inhaler correctly which 
was recognised in 120 events (Table 7). The mean number of errors per patient in a one month’s 
period was 11 (95% CI: 8-16) (Table 6). Besides, there was a trend of persistent technique error 
among some patients; for example, eight patients performed multiple inhalations more than 20 
times in a one-month period, seven patients had the error “blister present but no inhalation 
detected” more than 15 times and three patients had the error “no blister detected but inhalation 
present” more than 18 times, during the one-month observation period. 
There was no significant difference in TER between COPD and asthma patients (p=0.67). 
The comparison between both cohorts revealed that COPD patients audio records showed 
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more errors than those of asthma patients in a one-month period but this was not statistically 
significant (p=0.54) (Table 6).  
 
Based on a cut-off point of 20% for IT, 60% of patients (n=29/48) were found to have a high 
TER within a one-month usage of their DPI compared to 40% (n=19) who demonstrated a low 
TER. Only 2 patients (4%) did not commit any error during the one-month period, whereas the 
rest of patients (96%, n=46/48) committed errors during the one-month observation period. 
There was a strong negative association between actual adherence as measured by the EMD 





The current research provided an insight into the adherence level and technique rate and errors 
among asthma and COPD patients in community care in England using a quantifiable measure 
used in patient’s home. Analysis of the audio recordings from the chosen EMD showed that 
most patients made errors in both inhaler use and technique. In the current study, the data 
generated from the EMD provided an actual adherence rate of 42.7% when incorporating 
technique and interval between doses, with only eight patients (17%) out of the 48 having an 
actual adherence of ≥80%. This is comparable to the observational study conducted in Ireland 
among 103 asthma and COPD patients from primary care and community pharmacies (large 
multiple chain: Boots Pharmacy Inc.) using the same EMD 30. In the latter study, patients had 
a mean actual adherence of 47%, thus highlighting how ineffective and irregular inhaler use 
can be a common problem. The study showed that only 20% of patients were using their 
inhalers correctly and on time, i.e.:  having an actual adherence ≥80%. This highlights that the 
current findings from independent community pharmacies echo findings from multiple chain 
pharmacies in Ireland. Interestingly, another observational study 47 using the same EMD among 
179 COPD patients recruited upon hospital discharge in Ireland showed an even lower mean 
actual adherence of 22.6%, with only 6% of patients having an actual adherence ≥80%.  
 
Different methods have been employed to assess adherence in the literature. However, most 
studies were found to employ a mixture of subjective and objective methods, mainly a self-
reporting scale as a subjective method in conjunction with prescription refill adherence as an 
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objective method 4,18. However, it can be argued against the latter method being considered 
objective, given the findings of the current study and the fact that prescription refill adherence 
does not assess actual medication-taking behaviour 41,59. Comparisons between the different 
adherence measures in the current research revealed that in real-life situations, commonly used 
adherence measures such as dose-counter, self-reporting and prescription refill data are not 
accurate in reflecting the actual adherence behaviour of patients since these measures were 
significantly higher than the actual adherence rate as measured by the designated EMD. This 
is due to the fact that the chosen EMD provides objective information on both the point in time 
(temporal adherence- which provides an indication about intentional non-adherence) and the 
user technique (technique adherence, which may be considered as unintentional non-
adherence) each time the patient uses the inhaler 30,47. Hence, when both aspects are combined 
in the adherence calculations, a significantly lower actual adherence rate is calculated 
compared to established measures of adherence 30. This discordance in results between the 
actual adherence as measured by the EMD and the other established adherence measures was 
similarly reported by studies conducted in Ireland using the same EMD 30,47,48 . This in return 
calls into question the previously established adherence measures that are used in research 
(prescription refill, dose counter and self-reporting) and their applicability in real-life 
situations.  Given the generated results, the use of the designated EMD would be useful in 
clinical practice particularly for respiratory patients, who despite therapy optimisation, still 
show no improvement in their condition or still have their condition uncontrolled. HCPs do not 
usually know how a patient is using their inhaler once they take the inhaler home with them. 
Thus, the use of the designated EMD will help and guide HCPs to better identify and 
distinguish whether the progression of condition is influenced by adherence to therapy or 
deterioration in the condition. 
A previous research in Ireland, which aimed to compare the same EMD against established 
adherence measures, highlighted the absence of associations between actual adherence with 
prescription refill (using PDC and medication possession ratio) and self-reported adherence 48, 
but a small association between attempted adherence with prescription refill. The same Irish 
study also revealed significant correlations between adherence rates measured via the EMD 
with adherence from dose counter 48. In the current research, the attempted adherence was 
significantly associated with self-reported adherence but not with prescription refill, with no 
association between actual adherence and all other adherence measures. The association seen 
with self-reported adherence might be due to the fact that the self-reporting measure used in 
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the current research was specific to inhalers unlike the one used in the Irish study which 
examined adherence more generally and this was noted in the Irish study. The correlation 
between dose counter and adherence measures via the EMD in the Irish study can be attributed 
to the fact that participants were provided with the DPI by the research team and hence the 
DPIs were collected via a courier between 28-30 days following recruitment, hence adherence 
rate from dose counter was reflective of the one-month usage. Whereas in the current research, 
provision of the DPIs by the research team was not feasible, this resulted in extended usage of 
the DPI beyond the one-month period due to missing doses especially among poor adherers, 
although patients were instructed to return the DPI after a one-month period upon recruitment, 
hence the obtained adherence rate from dose counter was not reflective of the one-month usage 
across all patients.  
An interesting and important feature of the chosen EMD is the ability to identify the type of 
technique errors and quantify the frequency of these errors at the same time 30. The most 
common technique errors identified in the current research were multiple inhalations, drug 
priming present with no subsequent inhalation followed by failure to prime the inhaler correctly 
which occurred in 14.2% of all inhalations. However, in the two observational studies done by 
Sulaiman et al. 30,47  using the same EMD; one among 179 COPD patients upon hospital 
discharge 47 and the other among 103 asthma and COPD patients from primary care and 
community pharmacies 30; the most common errors identified were low peak inspiratory flow 
rate (<35 L/min), multiple inhalations followed by presence of drug priming with no 
subsequent inhalation. With respect to other studies which used the checklist method as a way 
to assess IT, a recent large systematic review over the past 40 years showed that the most 
common errors with DPIs were: no full exhalation before inhalation (46%), insufficient breath 
hold (37%) and incorrect preparation including loading the dose (29%) 32. This disparity can 
be attributed to the difference in the nature of the methods used to assess technique errors 
between the current study and the literature that use the checklist method for assessing IT.  
The aforementioned systematic review 32 also concluded that there has been an unacceptable 
high frequency of incorrect inhaler use over the past 40 years, while highlighting the necessity 
to identify new and better approaches to tackle this problem besides the already recommended 
strategies such as careful instruction, observation of IT, and individual matching of inhaler to 
meet patients’ needs and preferences 32.The review  32 based on studies which utilised the 
checklist method for assessing IT, concluded that the mean percentage of poor IT when using 
DPIs over the past 40 years was 23% 32. For studies utilising the checklist method, another 
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systematic review also estimated an overall error frequency of 60.9% of patients using DPIs 
committing at least one error, while noting a high level of heterogeneity between the reviewed 
studies 20. However, in the current study, 60% of patients (n=29/48) had a high TER 
(TER>20%) and the median TER was 30.1% for a one-month period usage among patients at 
home, as indicated by the EMD. In addition, only two (4%) patients did not commit any error 
during the one-month observation period.  
The mean number of errors per patient in the current study was 11, which indicates that even 
in the case of ideal adherence to twice-daily inhaled therapy (i.e. without missing any single 
dose); patients tend to get reduced amount or no drug in 11 uses out of 60 per month. 
Comparing to the two observational studies conducted by Sulaiman et al. 30,47 ; the mean 
number of errors per patient among 179 COPD patients discharged from hospital was 20 47, 
which is higher than the current findings. Whereas, the mean number of errors per patient 
among 103 COPD and asthma patients recruited from primary care and community pharmacies 
was 12 30, which is similar to the current findings. Another remarkable observation in the 
current research was that some patients exhibited a pattern of persistent technique error of the 
same type; this was identified through quantifying errors for each patient. This in return 
highlights the potential of technological developments such as the designated EMD in 
identifying technique errors outside clinical environments to assist in a problem, which does 
not seem to have improved over the last 4 decades 32. Education about IT should not be 
considered as a perfunctory practice, which means that HCPs are required to pay more attention 
to the quality of this education by making it clear, short in content and focused60. Thus, EMDs, 
such as the one used in this study, can facilitate the provision of individually tailored and 
focused interventions through discussing the personalised feedback provided by the device, 
which can elicit technique errors. According to social cognitive theory, performance mastery 
experience (i.e. doing something correctly) is one of the tactics to promote self-efficacy 22. 
Hence, if patients are made aware of the specific inhaler steps they do incorrectly using the 
feedback generated from the device, then they can rectify these errors, which in return could 
foster their confidence to use their inhalers in a correct manner 22. 
 
4.1. Strengths and limitations 
The current research has several strengths. This is the first study conducted in England using 
the designated EMD as a quantifiable measure of adherence outside clinical environment. 
Second, this was the first study to objectively quantify inhaler technique errors to preventer 
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inhaled therapy among patients in the community care setting in England. However, the results 
should be considered within the context of several limitations including; first the small sample 
size. Second, possibility of selection bias for community pharmacists and patients cannot be 
excluded since participation in research studies usually involves motivated people. Third, 
recruitment was limited across independent community pharmacies within South and West 
London. Fourth, recruitment was limited to patients using only salmeterol/fluticasone DPI, 
which limits the generalisability of the results. Fifth, patients were recruited based on self-
reported general practitioner (GP)-diagnosis about asthma or COPD, with confirmation being 
acquired from the community pharmacists but not from the patients’ GPs.  
 
5. Conclusion  
The current study demonstrates that while measures such as dose counter, prescription refill 
and self-reporting showed a high level of adherence among the observed patients, yet the 
objective data provided by the EMD showed a significantly lower actual adherence rate, 
reflecting how adherence remains very variable and problematic among patients in the 
community. The objective data showed that only 8 patients out of 48 used their inhalers 
correctly and on time. 
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Characteristics  All (N=48) Asthma (n=19) COPD (n=29) 
Age (y), median  (range) 65 (22-82) 65 (22-81) 65 (46-82) 
Female patients, n (%) 24 (50) 9 (47) 15 (52) 
Male patients, n (%) 24 (50) 10 (53) 14 (48) 
Smoking history, n (%) 
Non-smoker 
Current smoker  
Ex-smoker  
   
16 (33) 11 (58) 5 (17) 
10 (21) 0 (0) 10 (35) 
22 (46) 8 (42) 14 (48) 
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1(2) 0 (0) 1 (3) 
22 (46) 7 (37) 15 (52) 
12 (25) 5 (26) 7 (24) 
4 (8) 2 (11) 2 (7) 
9(19) 5 (26) 4 (14) 





   
10 (21) 4 (21) 6 ( 21) 
25 (52) 12 (63) 13 (45) 
5 (10) 1 (5) 4 (14) 
8 (17) 2 (11) 6 (21) 
Residential area, n (%) 
Kingston Upon Thames 




   
6 (12) 3 (15.7) 3 (10) 
20 (42) 10 (53) 10 (35) 
1(2) 0 (0) 1(3) 
14 (29) 3 (15.7) 11(38) 
7 (15) 3 (15.7) 4 (14) 
Flu vaccination, n (%)  
Yes  
No 
   
37 (77) 13 (68) 24 (83) 
11 (23) 6 (32) 5 (17) 
Pneumococcal vaccination, n (%) 
Yes 
No 
   
25 (52) 8 (42) 17 (59) 
23 (48) 11 (58) 12 (41) 
Presence of comorbidities, n (%)  
Yes  
No 
   
34 (71) 12 (63) 22 (76) 
14 (29) 7(37) 7(24) 
No. of comorbid conditions, 
median (range) 
2 (1-5) 1 (1-3) 2 (1-5) 
No. of medications, median 
(range) 
8 (2-16)  4 (2-16) 10(2-16) 
No. of GP visits per year, median 
(range) 
2 (1-6) 2 (1-6) 2 (1-6) 
Exacerbations during the last 
year, n (%) 
Yes  
No  
No. of exacerbations during the 
last year, median (range) 
   
22 (46) 5 (26) 17 (59) 
26 (54) 14 (74) 12 (41) 
3 (1-8) 3 (1-5) 3(1-8) 




No. of A & E visits during the last 
year, median (range) 
   
6 (12.5) 1(5) 5 (17) 
42 (87.5) 18 (95) 24 (83) 
2 (1-4) 4 (4) 2 (1-3) 
Hospital admissions during the 
last year, n (%)  
Yes  
No  
No. of hospital admissions during 




6 (12.5) 1 (5) 5 (17) 
42 (87.5) 18 (95) 24 (83) 
1 (1-3) 1 (1) 1 (1-3) 






Adherence measures All Asthma COPD 
Percentage attempted 
adherence as 
measured by the 
EMD, median  (range) 
72.7 (15.9-100) 68 (15.9-98.2) 78.8 (17.1-100) 
Percentage actual 
adherence as 
measured by the 
EMD, median (range)  
42.7 (0-96.4) 42 (0-96) 48.4 (0-93) 
Mean IAS score, mean 
(95%CI) 
4.43 (4.2-4.6) 4.27 (3.87- 4.7) 4.54 (4.2-4.7) 
Percentage MRA, 
median  (range) 
100** (33.3-
133.3) 
100 ( 33.3-116.7) 100 ( 50-133.3) 
Percentage PDC, 
median  (range) 
97.8** (33.3-100) 90.6 (33.3-100) 97.8 (46.1-100) 
Percentage adherence 
rate from dose 
counter, median  
(range)  
100** (76.7-100) 100 (95-100) 100 ( 76.7-100) 
Table (2):  Breakdown of different measures of adherence.  
Abbreviations:CI, Confidence Interval; IAS, Inhaler Adherence Scale; MRA, Medication Refill 
Adherence; PDC, Proportions of Days Covered.  
** Indicate statistical significant difference compared to attempted adherence and actual adherence as 






 Attempted adherence 
rate as measured by 










0%-19% 2 (4%) 1 1 
20%-39% 6 (12.5%) 2 4 
40-59% 5 (10.5%) 2 3 
60-79% 16 (33%) 11 5 
Adherence rate 
≥80%  
80-100% 19 (40%) 13 6 
Table (3): Attempted adherence range by 20% bands and the frequency of patients 























Dose counter adherence  47 (98) 1 (2) 
MRA 39 (81) 9 (19) 
PDC  37 (77) 11 (23) 
Table (4): Frequency and percentage of patients’ adherence according to the different 





rate as measured by 
the designated EMD 








0%-19% 15 (31%) 9 6 
20%-39% 7 (14.5%) 4 3 
40-59% 7 (14.5%) 5 2 
60-79% 11(23%) 6 5 
Adherence rate 
≥80%  
80-100% 8 (17%) 5 3 
Table (5): Actual adherence range by 20% bands and the frequency of patients within 
each band.   
 
 
 All Asthma COPD 
TER (%) per patient, 
median (range)  
30.1 (0-100) 34 (0-100) 27.5 (0-100) 
IT errors per patient, 
mean (95% CI) 
11 (8-16) 10 ( 6-17) 12 ( 8-19) 
Table (6): IT errors and TER as measured by the designated EMD.  











Errors in drug priming /drug 
blistering 
  
No drug priming , inhalation 
detected (failure to prime the 
device correctly) 
120 14.2 
Multiple drug priming  16 2 
Multiple drug priming and 
multiple inhalation  
10 1.2 
Dose dumping 0 0  
Total  146 17.4 
Errors in inhalation    
Exhales into the inhaler after 
drug priming and before 
inhalation 
30 3.6 
Drug priming present, no 
subsequent inhalation detected 
248 29.5 
Multiple inhalations  416 49.5 
Total  694 82.6 
Table (7): The type of different inhalation errors observed.  
 
Figure legends:  
Figure (1): The inhaler compliance assessment device attached to a dry powder inhaler. 
Permission to reproduce the figure of the inhaler compliance assessment device was granted 
from Vitalograph Ltd 40. 
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